While excavating clay cylinders in Syria, archaeologists discovered a rare find: an early writing system. The script has given scholars the new challenge of reinvestigating the timeline of alphabetic ...

Alphabet's stock entered 2025 at an undervalued level. A host of concerns were hanging over the tech giant a year ago. Alphabet's generative AI offerings have grown in popularity. All of those ...

Google parent Alphabet has agreed to buy Intersect Power, a data center and clean energy developer, for $4.75 billion in cash, plus the assumption of the company’s debt. The acquisition, which was ...

Google parent Alphabet said it will acquire Intersect, a data center company, for $4.75 billion in cash and the assumption of debt. Alphabet said the acquisition will help bring more data center and ...

On December 11, OpenAI release ChatGPT 5.2, the latest version of the widely used AI chatbot. As it does every time it releases a minor update, the company hailed its latest version as a “significant ...

Alphabet Inc. is set to book another sizable paper gain after SpaceX completes a tender offer that effectively values the closely held company at about $800 billion. SpaceX’s insider share sale was ...

Madrigal Pharmaceuticals shares were 12% higher, at $460.63, after company's third-quarter revenue jumped on sales of Rezdiffra. The stock hit its 52-week high of $464.98 earlier in the session, and ...

Alphabet beat Wall Street's expectations, reporting revenue of $102.35 billion vs. $99.89 billion adj. estimated. The company said it will increase its capital expenditures to a range of $91 billion ...

Madrigal Pharmaceuticals is reiterated as a Strong Buy, driven by Rezdiffra's rapid US launch and recent European approval. Q2 2025 saw Rezdiffra sales reach $213M and >23,000 patients, with Q3 ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) said it has signed a global licensing deal with CSPC Pharmaceutical (OTCPK:CSPCY) (OTCPK:CHJTF) for SYH2086, a new oral GLP-1 receptor agonist. As part of the ...

July 30 (Reuters) - U.S. drugmaker Madrigal Pharmaceuticals (MDGL.O), opens new tab has struck a licensing deal with CSPC Pharmaceutical Group (1093.HK), opens new tab that could be worth more than $2 ...